New treatments that target cancer cells using DNA cross-linking agents and vitamin C
Official title: Novel DNA cross-linking agents and combination strategies for tumor-specific activation
Funded at University of Wisconsin Milwaukee · NIH-10730787 · Data updated 2026-11-12
This study is exploring new treatments for cancer that use special agents activated by the higher levels of certain molecules found in cancer cells, aiming to make therapies more effective while protecting healthy cells, and it could help patients get better care with fewer side effects.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin Milwaukee NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | August 8, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $461,998 |
| NIH project number | 1R15CA277656-01A1 |
| Project ID | NIH-10730787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from novel therapeutic strategies.
✕Less likely to help
Patients with non-malignant conditions or those whose cancers do not exhibit elevated levels of reactive oxygen species may not benefit from this research.
What this research studies
This research investigates innovative DNA cross-linking agents that are activated by reactive oxygen species (ROS), which are found in higher levels in cancer cells. The approach focuses on developing prodrugs that become toxic specifically in the presence of ROS, aiming to enhance the effectiveness of cancer treatments. By combining these agents with vitamin C, which can increase ROS levels selectively in cancer cells, the research seeks to improve the targeting and efficacy of cancer therapies. Patients may benefit from more effective treatments that minimize harm to normal cells.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments that reduce side effects for patients.
How similar studies have gone: Previous research has shown promise in using ROS-activated therapies for cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
University of Wisconsin Milwaukee
Milwaukee, United States Active
Researchers
- Principal investigator: Peng, Xiaohua — University of Wisconsin Milwaukee
- Study coordinator: Peng, Xiaohua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.